Substance Withdrawal Syndrome
26
0
0
23
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 26 trials
100.0%
+13.5% vs benchmark
19%
5 trials in Phase 3/4
22%
5 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (26)
Efficacy of XYZ for Withdrawal Syndrome
Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool
Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Abuse and Addiction in ICU
EA for PAAS: A pRCT
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?
Nicotine Replacement Therapy in the Intensive Care Unit
Opioid Withdrawal Symptoms in Critically Ill Patients
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
Effect of Ondansetron for Withdrawal Symptoms
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Acute Withdrawal From Smoked Cocaine - 9
Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program
Process Evaluation Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal in ENT
Stopping Benzodiazepines and Related Molecules Among Elderly Living in Residential Institutions
Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study
Effects of Dynorphin 1-13 on Heroin Addiction - 1